Platform-Derived Leads
Oncology, Inflammation, Infectious Disease, Microbiome Dynamics
Key Facts
About Sirenas
Sirenas is a San Diego-based, private drug discovery company pioneering the use of computational metabolomics to mine marine and microbiome-derived natural products for novel therapeutics. The company's proprietary ATLANTIS platform analyzes complex metabolomic datasets to rapidly identify bioactive small molecules with potential against high-value targets in areas like oncology, inflammation, and infectious diseases. Founded in 2013 by a team including CEO Eduardo Esquenazi, Sirenas has built a large, sustainably sourced marine sample library and has attracted non-dilutive funding, such as a grant from the Bill & Melinda Gates Foundation. It operates as a preclinical platform company, generating therapeutic leads for potential partnership or internal development.
View full company profile